Skip to main content
BIOVENTIX PLC logo

BIOVENTIX PLC — Investor Relations & Filings

Ticker · BVXP ISIN · GB00B4QVDF07 LEI · 213800225MHX7LZQY108 IL Manufacturing
Open in API
Filings indexed 211 across all filing types
Latest filing 2024-10-25 Major Shareholding Noti…
Country GB United Kingdom
Listing IL BVXP

About BIOVENTIX PLC

https://www.bioventix.com/

Bioventix PLC is a biotechnology company that specializes in the development, creation, and commercial supply of high-affinity sheep monoclonal antibodies (SMAs). These antibodies are utilized by global diagnostic companies as critical components in clinical diagnostic platforms, particularly for blood testing immunoassays. The company's portfolio supports a variety of applications, including diagnostics for cardiovascular conditions (troponin), oncology, and neurodegenerative diseases such as Alzheimer's. In addition to its core antibody products, Bioventix also provides ELISA kits for monitoring exposure to industrial pollutants and offers contract services for the development of new SMAs for healthcare organizations.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' header and the concluding paragraph mentioning RNS and the London Stock Exchange. The content itself is a 'TR-1: Standard form for notification of major holdings,' which details changes in share ownership thresholds by an entity (Sanford Deland Asset Management Ltd). This type of filing, reporting changes in significant shareholdings, directly corresponds to the Major Shareholding Notification category (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2024-10-25 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'Standard form for notification of major holdings' and carries an 'RNS Number'. It details changes in share ownership ('An acquisition or disposal of shares') by a specific entity (Schroders PLC), crossing a notification threshold (5.467015%). This structure perfectly matches the definition of a Major Shareholding Notification, which is categorized under the code MRQ.
2024-10-16 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document explicitly announces a transaction involving a company director (Chief Financial Officer, Bruce Hiscock) purchasing the company's own shares. The text contains keywords like 'Director Dealing', 'Purchase of Ordinary Shares', and includes a formal notification structure mandated by regulations (EU Market Abuse Regulation) detailing the transaction by a person discharging managerial responsibilities. This directly corresponds to the definition of Director's Dealing (DIRS). The presence of the RNS Number and the LSE footer confirms it is a regulatory announcement, but the specific content points to DIRS over the general RNS category.
2024-04-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and contains fields related to the 'Identity of the issuer', 'Reason for the notification' (specifically 'An acquisition or disposal of voting rights'), 'Details of person subject to the notification obligation', and 'Total positions of person(s) subject to the notification obligation' showing percentage changes in voting rights (e.g., 11.87% vs 12.80%). This structure is characteristic of a regulatory filing notifying a change in significant share ownership, which corresponds to the Major Shareholding Notification category (MRQ). Although it is distributed via RNS, the content itself is a specific regulatory disclosure form (TR-1), making MRQ the most precise classification over the general RNS fallback.
2024-04-12 English
Interim Results
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Interim Results for the six months ended 31 December 2023' for BioVentix PLC. It contains comprehensive financial statements, including a Statement of Comprehensive Income, Statement of Financial Position, and Statement of Cash Flows for the specified interim period. It is not merely an announcement of a report, but the report itself, containing substantive financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. H1 2024
2024-03-25 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document explicitly announces a 'Director Dealing' transaction. It details the sale of ordinary shares by the Chief Executive Officer (Peter Harrison) on a specific date (29 January 2024). The structure, including the RNS Number, the notification table detailing the transaction, and the reference to EU Market Abuse Regulation, confirms this is a mandatory disclosure of insider trading activity. This directly matches the definition for Director's Dealing (Code: DIRS).
2024-01-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.